![Page 1: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/1.jpg)
A Quality Perspective on Continuous
BiomanufacturingFrank Lammers
22-Oct-2013
![Page 2: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/2.jpg)
| 2
The storyline in Quality…
…circles around three basic questions:
- Where do we see risks ?- Where do we see risks ?
- How do we rank those ?- How do we rank those ?
- How do we grip them in an - How do we grip them in an efficient control modus ?efficient control modus ?
![Page 3: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/3.jpg)
| 3
…how to apply to continuous biomanufacturing ?
![Page 4: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/4.jpg)
| 4
Outline
●Process design objectives, perceived risks & potential mitigations
●Specific Quality Assurance objectives, perceived risks & potential mitigations
●Continuous biomanufacturing and the QbD arena
●Conclusion
![Page 5: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/5.jpg)
| 5
Outline
●Process design objectives, perceived risks & potential mitigations
●Specific Quality Assurance objectives, perceived risks & potential mitigations
●Continuous biomanufacturing and the QbD arena
●Conclusion
![Page 6: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/6.jpg)
| 6
Consistent Product Quality
● Objective● High and consistent product quality through operation @ optimal
steady state
● Perceived risk● Non-reliable and/or slow feedback control to really reach steady-
state-conditions● Reliability and robustness of process automation (soft- and hardware)● Different loading of columns in continuous chromatography impacts
purification outcome
● Potential mitigation● validated PAT (if available)● Appropriate equipment qualification and software validation
![Page 7: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/7.jpg)
| 7
Decrease of impurity level
● Objective● Lower level of impurities in the bioreactor due to high cell viability
reduces DSP efforts
● Perceived risk● impurity trending with less priority during continuous biomanufacturing● Process related impurities (eg HCP) may increase in long operation
mode
● Potential mitigation● continuous impurity monitoring by means of customized PAT, eg on-
line-HPLC/UPLC● Definition of alert & action level to assess OOT results
![Page 8: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/8.jpg)
| 8
Decrease of holding times
● Objective● Improved product quality through tremendous decrease of product
hold time by minimization of residence times and elimination of multiple non-value-added hold steps
● Less intermediate testing and stability studies through elimination of hold steps
● Perceived risk● Elimination of holding steps decreases time-buffer and flexibility to re-
adjust industrialized process in time while being in operation● No intermediate processing-stop
● Potential mitigation● Time- or volume-based segmentation of manufacturing-flow to
coordinate re-adjustment in concrete segments
![Page 9: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/9.jpg)
| 9
Less Bioburden
● Objective● Minimized bioburden risk through closed system operation
● Perceived risk● higher probability of contamination issues due to long term manufacturing
● Potential mitigation● Strong focus on contamination control both in equipment qualification and
microbio monitoring design
![Page 10: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/10.jpg)
| 10
Lower environmental monitoring
● Objective● Low environmental monitoring due to closed system operation in lower
environmental class
● Perceived risk● Decrease of sterile barrier due to sampling process in lower
environmental class
● Potential mitigation● local sampling booth
![Page 11: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/11.jpg)
| 11
Outline
●Process design objectives, perceived risks & potential mitigations
●Specific Quality Assurance objectives, perceived risks & potential mitigations
●Continuous biomanufacturing and the QbD arena
●Conclusion
![Page 12: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/12.jpg)
| 12
Batch definition
● Objective● Crystal clear batch definition to link starting materials and in-process-
information with final product and to assure post-manufacturing traceability (eg. recall-situation)
● Perceived risk● In- and post-process events (eg., deviation, OOT, recall) potentially
affect whole manufacturing campaign instead of limited batch volume
● Potential mitigation● Batch record design reflecting time- or volume-based segmentation of
whole manufacturing campaign
![Page 13: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/13.jpg)
| 13
Change Control Management
● Objective● Continuous improvement of industrialized processes by means of
change control management
● Perceived risk● Due to long processing times of continuous manufacturing, probably
longer time needed to generate data for evaluation of envisaged changes
● Potential mitigation● Development in QbD paradigm to result into design space ● changes only within elaborated design space
![Page 14: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/14.jpg)
| 14
Deviation/OOS handling
● Objective● Deviation/OOS assignment
● Perceived risk● No clarity how far deviation/OOS affect whole manufacturing
campaign or only limited segment (time/volume)
● Potential mitigation● be able to isolate non-spec- from in-spec-segments● Set deviation/OOS in order with volume/time based segmentation and
resulting batch pedigree
![Page 15: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/15.jpg)
| 15
Validation design
● Objective● State-of-the art validation design reflecting current experiences in
biomanufacturing (x process runs, LIVCA batches, cleaning, product change over)
● Perceived risk● Stock piling through lengthy validation runs and following data
evaluation in conflict with product stability
● Potential mitigation● CM specific validation (different from batch/semi-batch operations)● Concurrent validation approaches● Exclude stock piling (depending on product stability)
![Page 16: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/16.jpg)
| 16
Viral safety
● Objective● Validation of viral removal / safety
● Perceived Risk● Previously used spiking study design may not reflect in continuous
chromatography different loading status of columns
● Potential mitigation● Spiking experiments tailored to continuous chromatography● Higher effort with more spiking experiments
![Page 17: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/17.jpg)
| 17
Cleaning Aspects
● Objective● Cleaning processes
● Perceived Risk● No cleaning of equipment during continuous manufacturing increases
eg. risk of membrane moulding, DSP performance etc.
● Potential mitigation● Design cleaning process/agents/detergents with special focus on CM
characteristics● Adapt frequency of cleaning & (membrane) maintenance● Include tailored sanitising of chromatography process
![Page 18: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/18.jpg)
| 18
Outline
●Process design objectives, perceived risks & potential mitigations
●Specific Quality Assurance objectives, perceived risks & potential mitigations
●Continuous biomanufacturing and the QbD arena
●Conclusion
![Page 19: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/19.jpg)
| 19
ICH Q landscape on biotech manufacturing
Wild vector
Host cell
Expression system (1 clone)
Master cell bank
Working cell bank
Upstream processing
Downstream processing
Drug Substance
Sterile filtration / aseptic filling
Drug Product
Expression vector
Gene of interest
Geneticdevelopment
Cell banks
Production
SterilisationAseptic filling
Q5AQ5BQ5DQ5E
Q5AQ5CQ5EQ6BQ11Q5EQ6BQ8Q8R
Q7A
Q9Q10
QbD package
![Page 20: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/20.jpg)
| 20
Quality by Design (QbD)
„A systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management“
ICH Q8(R2)
![Page 21: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/21.jpg)
| 21
Elements of QbD approachQ
ualit
y T
arg
et P
rodu
ct P
rofil
e
Riskassessment
Riskassessment
Riskassessment
A-Mab Case study, www.casss.org
Continuous Biomanufacturing
ProcessAnalytical
Technology
Key elements in QbDKey elements in CM
![Page 22: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/22.jpg)
| 22
Traditional vs PAT approach
Traditional approach• Process developed, „freezed“,
validated through 3 commercial batches
• Process assurance via SOPs, training etc.
• QC performed later with product off-line-testing in lab
PAT approach• on-line/at-line analysis allows flexible adaption
• statistical based process control
• (release without off-line-tests)
•Static endproduct oriented claim•Process as black-box
•Dynamic object oriented•Process understood
Closed loop Bioprocess control for improved & predicted product quality-
+
![Page 23: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/23.jpg)
| 23
QbD & continuous biomanufacturing in perfect fit
● Continuous biomanufacturing ambassador in catalyzing QbD
● As clear difference to batch manufacturing, continuous biomanufacturing in marriage with PAT only ● but batch-/semi-batch manufacturing in use of PAT as well
● Appropriate PAT is key● NIR, UV/VIS, on-line-HPLC/UPLC etc.
● Risk based approaches as enabler to rank quality attributes and control strategy elements
● Benefits as highlighted in process design objectives
![Page 24: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/24.jpg)
| 24
Outline
●Process design objectives, perceived risks & potential mitigations
●Specific Quality Assurance objectives, perceived risks & potential mitigations
●Continuous biomanufacturing and the QbD arena
●Conclusion
![Page 25: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/25.jpg)
| 25
Back to the original questions…
- Where do we see risks ?- Where do we see risks ?
- How do we rank those ?- How do we rank those ?
- How do we grip them in an - How do we grip them in an
efficient control modus ?efficient control modus ?
![Page 26: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/26.jpg)
| 26
…and the resulting conclusion
![Page 27: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/27.jpg)
| 27
Take home messages
● In comparison to batch manufacturing, continuous biomanufacturing certainly characterized with new & challenging but manageable QA tasks
● Several risk identified, but a couple of potential mitigations already available
● Some mitigations probably active since years, others to be further developed or refined
● Currently no QA show stoppers visible
![Page 28: A Quality Perspective on Continuous Biomanufacturing](https://reader030.vdocuments.site/reader030/viewer/2022020106/56813f5b550346895daa2a64/html5/thumbnails/28.jpg)
| 28